A5079640370- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Botulinum Toxin and Related Neurological Disorders
- Dysphagia Assessment and Management
- Health Systems, Economic Evaluations, Quality of Life
- Psoriasis: Treatment and Pathogenesis
- Inflammatory Bowel Disease
- IL-33, ST2, and ILC Pathways
- Restless Legs Syndrome Research
- Occupational Therapy Practice and Research
Hospital de Manises
2019
Background: Parkinson's disease (PD) is a neurodegenerative disorder that the second most common after Alzheimer's disease.PD includes both "motor" and "non-motor" symptoms, one of which pain.The aim this study was to investigate clinical characteristics pain in patients with PD.Methods: This cross-sectional included 250 diagnosed PD, 70% had mild moderate PD (stages 2/3 Hoehn Yahr scale).The average age 67.4 years, duration since diagnosis 7.1 years.Relevant data collected from were...
Because of the prevalence and impact sleep disorders in Parkinson's disease (PD), valid instruments for their evaluation monitoring are necessary. However, some nocturnal may go unnoticed by patients themselves.To validate a pan-Spanish version Disease Sleep Scale Version 2 (PDSS-2) to test relationships between PDSS-2 roommate version.PD (n = 399) from seven Spanish-speaking countries were included. In addition tested scales, measures both motor nonmotor manifestations applied....
Safinamide is a new add-on drug to levodopa for the treatment of Parkinson's disease (PD) with motor fluctuations. Due recent incorporation safinamide into routine clinical practice, no post-authorisation phase IV studies on safety have been conducted date. This study provides management guidelines based opinion group experts in movement disorders. project was developed 2 phases: 16 local meetings 1 and national meeting 2. The followed pre-established agenda. present practice are main...
In recent years we have witnessed a growing tendency to opt for the use of dopamine agonists (DA) as treatment Parkinson's disease (PD), with aim delaying far possible development fluctuations and dyskinesias. Yet, levodopa continues be most effective antiparkinson drug is probably one that improves greatest number symptoms disease. This article reports on results comprehensive review literature dealing benefits risks in patients PD which was conducted by group expert neurologists members...
La safinamida es un nuevo fármaco para el tratamiento de pacientes con enfermedad Parkinson (EP) fluctuaciones como complementario a levodopa. Dado que por momento aún no existen estudios fase IV postautorización debido la reciente incorporación práctica clínica habitual, interés este proyecto radica en desarrollo una guía manejo clínico basada las opiniones expertos trastornos del movimiento. Este se desarrolló 2 fases: primera constó 16 reuniones locales y segunda consistió reunión...